Author’s note: The current U.S. political environment is unsuitable for implementing a system permitting patients to use late-stage experimental drugs if they choose. That environment would improve if ...

Excerpted from the booklet More Choices, Better Health: Free to Choose Experimental Drugs, by Bartley J. Madden–the last in a several-part series. The complete ...

But she also noted that complaints about dual tracking declined in September, and she expressed optimism that the practice will stop now that the new standards are enforceable. "In October and ...

After a decade of digital development and evolution, it was already clear at the dawn of 2020 that organizations agile enough to adjust and transform stood the best chance of growing their businesses.

In biotechnology, timing is everything. Whether advancing a novel therapy or scaling a platform, companies often reach a pivotal point: go public or sell. Increasingly, biotech executives are choosing ...